NeuroSense TherapeuticsNRSN
NRSN
About: NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Employees: 15
0
Funds holding %
of 7,299 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1.96% less ownership
Funds ownership: 2.8% [Q4 2024] → 0.84% (-1.96%) [Q1 2025]
15% less funds holding
Funds holding: 13 [Q4 2024] → 11 (-2) [Q1 2025]
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
77% less capital invested
Capital invested by funds: $776K [Q4 2024] → $181K (-$595K) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$14
471%
upside
Avg. target
$14
471%
upside
High target
$14
471%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert | 471%upside $14 | Buy Initiated | 12 May 2025 |
Financial journalist opinion
Positive
Benzinga
1 month ago
Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights
Last Wednesday, NeuroSense Therapeutics Ltd. NRSN said it scaled up its production of PrimeC to a commercial scale.
Neutral
PRNewsWire
1 month ago
NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch
NeuroSense Announces Global CDMO Selection and Manufacturing Scale-Up, Enabling Rapid Pathway to Commercialization for What is Projected to be a $100-150M Canadian Market Opportunity CAMBRIDGE, Mass. , May 7, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Neutral
PRNewsWire
1 month ago
NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update
Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about ongoing partnership discussions with global pharmaceutical company CAMBRIDGE, Mass. , April 24, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Neutral
PRNewsWire
2 months ago
NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment
New miRNA findings unveiled at the AAN, reveal key biological mechanisms behind PrimeC's clinical benefit in ALS. CAMBRIDGE, Mass.
Neutral
PRNewsWire
2 months ago
NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates
Phase 2b study completed in amyotrophic lateral sclerosis (ALS) demonstrated lead asset PrimeC slows disease progression and functional decline Ongoing partnership discussions to advance PrimeC to Phase 3 study in ALS and commercialization Phase 3 study design for PrimeC in ALS aligned with FDA; planned initiation in 2025 CAMBRIDGE, Mass. , April 7, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Neutral
PRNewsWire
2 months ago
NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting
Two presentations in the General Neurology and Late Breaker sessions will respectively cover new clinical and microRNA data from NeuroSense CAMBRIDGE, Mass. , April 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics, Ltd.
Neutral
Business Wire
2 months ago
Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug
NEW YORK--(BUSINESS WIRE)--Market News Alerts Reports: NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)* has announced significant progress toward the early commercialization of PrimeC in Canada. According to a Form 6-K filed with the SEC this morning, Health Canada has invited the company to a pre-New Drug Submission (pre-NDS) meeting to discuss a potential Notice of Compliance/conditional (NOC/c) regulatory pathway for PrimeC as a treatment for Amyotrophic Lateral Sclerosis (ALS). NeuroSense is ta.
Neutral
Business Wire
3 months ago
PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape
NEW YORK--(BUSINESS WIRE)---- $NRSN #ALS--PESG Research releases a new report covering NeuroSense Therapeutics (NASDAQ: NRSN)* and its recent developments: In a medical landscape hungry for innovation, NeuroSense Therapeutics (NASDAQ: NRSN) stands at the forefront of a potential revolution in ALS treatment, developing a groundbreaking combination therapy that could fundamentally transform the approach to one of the most devastating neurological disorders. With clinical data showing a remarkable 36% reduction.
Neutral
PRNewsWire
5 months ago
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement
NeuroSense in Compliance with all Nasdaq Listing Requirements CAMBRIDGE, Mass. , Jan. 6, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Neutral
PRNewsWire
5 months ago
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS
Binding Term Sheet with a leading global pharmaceutical company includes a substantial upfront payment and funding for the Phase 3 study Additionally, milestone payments and double-digit royalties on annual net sales The transaction is subject to finalization of a definitive agreement, anticipated in Q1 2025 CAMBRIDGE, Mass. , Dec. 23, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Charts implemented using Lightweight Charts™